CALENDAR

Location: Charleston, SC  (In-person or vis Live Streaming Webcast)

Visit Event Website

This three-day intensive conference, held on June 24-26, 2021 in Charleston, South Carolina, addresses all the issues confronting clinicians who treat challenging patients with diabetes, hypertension, and dyslipidemia and how to apply this knowledge to everyday practice.

Over the past several years controversies in the appropriate target for Hemoglobin A1C, BP, and LDL-Cholesterol on outcome improvement continue to occur in Type 2 Diabetes, Hypertension, and Dyslipidemia, respectively. Despite the results from the ACCORD, VADT, and ADVANCE studies suggesting the benefits of reducing A1C on macrovascular disease with a more intensive strategy remains unclear and even harmful, individualized A1C targets for those with newly diagnosed diabetes are often recommended. In addition, controversy continues to exist in cholesterol control as recent guidelines suggest that one should decide on the intensity of statin-based therapy in those at risk for or with established ASCVD rather than a specific LDL-cholesterol goal to improve clinical outcome. Finally, the recent SPRINT trial found that lower targets for BP reduction can and should be achieved in high-risk adults with hypertension.